Jun 22, 2020
New Preclinical Data on ALKS 4230 in Combination With Lucitanib to be Presented at 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
Jun 04, 2020
Alkermes to Take Part in 41st Annual Goldman Sachs Global Healthcare Conference
May 14, 2020
Alkermes Presents New Data From Schizophrenia Portfolio at Virtual 2020 Congress of the Schizophrenia International Research Society
May 11, 2020
Alkermes Announces Expansion of Patient Services and Provider Network to Support Uninterrupted Access to ARISTADA® and VIVITROL® During COVID-19 Crisis
May 06, 2020
Alkermes Announces Upcoming Presentation at the Bank of America Securities Virtual Health Care Conference
May 04, 2020
Alkermes Launches COVID-19 Relief Fund to Support Innovative Programs Helping Vulnerable Patient Communities
Apr 29, 2020
Alkermes Plc Reports First Quarter 2020 Financial Results and Provides COVID-19 Related Business Update
Apr 22, 2020
Alkermes to Host Conference Call to Discuss First Quarter 2020 Financial Results
Apr 22, 2020
Alkermes Announces Publication of Preclinical Data for ALKS 4230 in the Journal for ImmunoTherapy of Cancer
Mar 04, 2020
Journal of Clinical Psychiatry Publishes Data from Alkermes' Phase 3 ENLIGHTEN-1 Efficacy Study of ALKS 3831 in Patients With Schizophrenia
Feb 24, 2020
Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 40th Annual Health Care Conference
Feb 06, 2020
Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2019 Financial Results
Jan 28, 2020
Alkermes Announces U.S. Food and Drug Administration Acceptance of ALKS 3831 New Drug Application for Treatment of Schizophrenia and Bipolar I Disorder
Jan 08, 2020
Alkermes' Corporate Presentation to be Webcast at the 38th Annual J.P. Morgan Healthcare Conference
Nov 26, 2019
Alkermes to Present at the Evercore ISI 2nd Annual HealthCONx Conference
Nov 25, 2019
Alkermes Completes Acquisition of Rodin Therapeutics
Nov 19, 2019
Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder
Nov 18, 2019
Alkermes to Acquire Rodin Therapeutics
Nov 12, 2019
Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences
Nov 12, 2019
Alkermes Announces Receipt of $150 Million Milestone Payment from Biogen Related to FDA Approval of VUMERITY(TM)